Increased awareness of infertility boosting the global menotropin market

The global menotropin market is forecast to grow at a CAGR growth rate of around 1.32% between the forecast period 2012 to 2016. There are a number of key drivers in the current industry which are aiding growth, including an increased number of infertility case, and the growing awareness of prevention and treatment programs for infertility.

One of the key drivers of growth in the menotropin industry at the current time is the increasing number of awareness programs regarding the prevention and treatment of infertility. Depending of different regions of the world, these programs come from either governmental or non-governmental organisations. On top of this, a number of key companies in the industry have launched their own awareness campaigns on the various technologies available, including US pharmaceuticals company Merck Serono.

Another key driver of growth in the industry is the increased number of cases of infertility. The top reasons for increased infertility include a stressful life, heavy smoking, sedentary lifestyles, increased population figures.

Despite a number of key drivers which are expected to help aid revenue growth in the industry, there are also a number of challenges which the global menotropin market will have to overcome if it is to achieve its full potential over the forecast period. One of the key challenges to growth is expected to be the adverse side-effects of menotropin. Anther issue which may hinder growth is the development of alternative treatment options for infertility, including other fertility drugs, IVF procedures, surrogacy and intracytoplasmic sperm injection.

The two key players in this global menotropin industry are Ferring Pharmaceuticals Inc and Merck Serono.

For more information on the Global menotropin market, see the latest research: Global Menotropin Market Research

Follow us on Twitter @CandMResearch